Gene Therapy for Parkinson Disease

Chi‐Jing Choong, Osaka University Graduate School of Medicine, Osaka, Japan
Hideki Mochizuki, Osaka University Graduate School of Medicine, Osaka, Japan

Published online: November 2013

DOI: 10.1002/9780470015902.a0025023

Abstract

Parkinson disease (PD) presents several features including the relative selective localisation of pathology to the substantia nigra and well‐defined motor symptoms caused by dopaminergic degeneration that make it an ideal target for gene therapy. Parallel progress in viral vector systems has made it possible to deliver therapeutic genes directly into the brain with reasonable safety. To date, gene therapy for PD is mainly based on symptomatic approaches that involve enzyme‐replacement strategies to restore dopamine (DA) levels or correct the functional perturbation of the basal ganglia caused by DA loss and disease‐modifying approaches that depend on delivery of neurotrophic factors and alteration of genetic causes of PD to protect neuronal functions and slow down or even halt disease progression. As supported by the increasing preclinical and clinical evidence, gene therapy may be a promising treatment to relieve the disabling nature of PD.

Key Concepts:

  • Gene therapy for PD focusses on symptomatic approach that involves enzyme‐replacement strategy and disease‐modifying approach that depends on addition of neurotrophic factors.

  • Intrastriatal expression of genes TH, AADC and GCH, the three key enzymes for DA biosynthesis, can compensate for the decreased levels of DA in PD patients.

  • An approach aiming at modulating STN activity is done by delivering gene GAD, the rate‐limiting enzyme for GABA synthesis.

  • Neurotrophic factors including GDNF and NTN have potent trophic activity on dopaminergic neurons and play essential roles in the protection and restoration of neuronal cells.

  • Novel viral vectors are capable of delivering genetic materials to target cells and inducing sustained transgene expression.

  • Four candidates for PD gene therapy including EIAV‐AADC‐TH‐GCH, AAV2‐AADC, AAV2‐GAD and AAV2‐NTN are currently under clinical trial evaluation.

Keywords: gene therapy; Parkinson disease; viral vector; aromatic l‐amino acid decarboxylase; glial cell line‐derived neurotrophic factor; glutamic acid decarboxylase; neurturin; alpha synuclein; parkin

Figure 1.

An overview of changes in basal ganglia function in PD patients (a) before and (b) after gene therapies. In PD state, loss of DA in the striatum results in diminished inhibitory tone in STN. STN becomes hyperactive and leads to excessive stimulation of GPi/SNpr and consequent inhibition of the thalamus causing the reduction in cortical outflow. Gene therapies that involve prevention of dopaminergic neurodegeneration, restoration of DA level in the striatum and provision of GABA in GPi/SNpr are believed to restore normal thalamic tone. Modified from Muramatsu . © Annals of Neurosciences.
Figure 2.

Current progress of gene therapy for PD.
close

References

Aguiar AS Jr , Tristão FS , Amar M et al. (2013) Parkin‐knockout mice did not display increased vulnerability to intranasal administration of 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP). Neurotoxicity Research 24(2): 280–287.

Airavaara M , Harvey BK , Voutilainen MH et al. (2012) CDNF protects the nigrostriatal dopamine system and promotes recovery after MPTP treatment in mice. Cell Transplantation 21(6): 1213–1223.

Akerud P , Canals JM , Snyder EY and Arenas E (2001) Neuroprotection through delivery of glial cell line‐derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. Journal of Neuroscience 21(20): 8108–8118.

Azzouz M , Martin‐Rendon E , Barber RD et al. (2002) Multicistronic lentiviral vector‐mediated striatal gene transfer of aromatic l‐amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. Journal of Neuroscience 22(23): 10302–10312.

Bäck S , Peränen J , Galli E et al. (2013) Gene therapy with AAV2‐CDNF provides functional benefits in a rat model of Parkinson's disease. Brain and Behavior 3(2): 75–88.

Bankiewicz KS , Forsayeth J , Eberling JL et al. (2006) Long‐term clinical improvement in MPTP‐lesioned primates after gene therapy with AAV‐hAACD. Molecular Therapy 14: 564–570.

Biju KC , Santacruz RA , Chen C et al. (2013) Bone marrow‐derived microglia‐based neurturin delivery protects against dopaminergic neurodegeneration in a mouse model of Parkinson's disease. Neuroscience Letters 535: 24–29.

Chen L , Huang E , Wang H , Qiu P and Liu C (2013) RNA interference targeting α‐synuclein attenuates methamphetamine‐induced neurotoxicity in SH‐SY5Y cells. Brain Research 1521: 59–67.

Christine CW , Starr PA , Larson PS et al. (2009) Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology 73(20): 1662–1669.

Cunningham LA and Su C (2002) Astrocyte delivery of glial cell line‐derived neurotrophic factor in a mouse model of Parkinson's disease. Experimental Neurology 174(2): 230–242.

Decressac M , Kadkhodaei B , Mattsson B et al. (2012) α‐Synuclein‐induced down‐regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Science Translational Medicine 4(163): 163ra156.

Decressac M , Ulusoy A , Mattsson B et al. (2011) GDNF fails to exert neuroprotection in a rat α‐synuclein model of Parkinson's disease. Brain: 134(Pt8): 2302–2311.

During MJ , Samulski RJ , Elsworth JD et al. (1998) In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP‐treated monkeys using an AAV vector. Gene Therapy 5(6): 820–827.

Eberling JL , Jagust WJ , Christine CW et al. (2008) Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70(21): 1980–1983.

Emborg ME , Carbon M , Holden JE et al. (2007) Subthalamic glutamic acid decarboxylase gene therapy: changes in motor function and cortical metabolism. Journal of Cerebral Blood Flow and Metabolism 27(3): 501–509.

Eslamboli A , Georgievska B , Ridley RM et al. (2005) Continuous low‐level glial cell line‐derived neurotrophic factor delivery using recombinant adeno‐associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. Journal of Neuroscience 25(4): 769–777.

Fan DS , Ogawa M , Fujimoto KI et al. (1998) Behavioral recovery in 6‐hydroxydopamine‐lesioned rats by cotransduction of striatum with tyrosine hydroxylase and aromatic l‐amino acid decarboxylase genes using two separate adeno‐associated virus vectors. Human Gene Therapy 9(17): 2527–2535.

Gasmi M , Brandon EP , Herzog CD et al. (2007) AAV2‐mediated delivery of human neurturin to the rat nigrostriatal system: long‐term efficacy and tolerability of CERE‐120 for Parkinson's disease. Neurobiology of Disease 27(1): 67–76.

Gill SS , Patel NK , Hotton GR et al. (2003) Direct brain infusion of glial cell line‐derived neurotrophic factor in Parkinson disease. Nature Medicine 9(5): 589–595.

Gorbatyuk OS , Li S , Nash K et al. (2010) In vivo RNAi‐mediated alpha‐synuclein silencing induces nigrostriatal degeneration. Molecular Therapy 18(8): 1450–1457.

Hayashita‐Kinoh H , Yamada M , Yokota T , Mizuno Y and Mochizuki H (2006) Down‐regulation of alpha‐synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model. Biochemical and Biophysical Research Communications 341(4): 1088–1095.

Imaizumi Y , Okada Y , Akamatsu W et al. (2012) Mitochondrial dysfunction associated with increased oxidative stress and alpha‐synuclein accumulation in PARK2 iPSC‐derived neurons and postmortem brain tissue. Molecular Brain 5(1): 35.

Jarraya B , Boulet S , Ralph GS et al. (2009) Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Science Translational Medicine 1(2): 2ra4.

Kaplitt MG , Feigin A , Tang C et al. (2007) Safety and tolerability of gene therapy with an adeno‐associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369(9579): 2097–2105.

Kells AP , Eberling J , Su X et al. (2010) Regeneration of the MPTP‐lesioned dopaminergic system after convection‐enhanced delivery of AAV2‐GDNF. Journal of Neuroscience 30(28): 9567–9577.

Kemeny S , Dery D , Loboda Y et al. (2012) Parkin promotes degradation of the mitochondrial pro‐apoptotic ARTS protein. PLoS One 7(7): e38837.

Khodr CE , Sapru MK , Pedapati J et al. (2011) An α‐synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Research 1395: 94–107.

Kirik D , Rosenblad C , Bjorklund A and Mandel RJ (2000) Long‐term rAAV‐mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. Journal of Neuroscience 20(12): 4686–4700.

Kordower JH , Herzog CD , Dass B et al. (2006) Delivery of neurturin by AAV2 (CERE‐120)‐mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP‐treated monkeys. Annals of Neurology 60(6): 706–715.

Lang AE , Gill S , Patel NK et al. (2006) Randomized controlled trial of intraputamenal glial cell line‐derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology 59(3): 459–466.

LeWitt PA , Rezai AR , Leehey MA et al. (2011) AAV2‐GAD gene therapy for advanced Parkinson's disease: a double‐blind, sham‐surgery controlled, randomised trial. AAV2‐GAD gene therapy for advanced Parkinson's disease: a double‐blind, sham‐surgery controlled, randomised trial. Lancet Neurology 10(4): 309–319.

Liu B , Traini R , Killinger B , Schneider B and Moszczynska A (2013) Overexpression of parkin in the rat nigrostriatal dopamine system protects against methamphetamine neurotoxicity. Experimental Neurology 247: 359–372.

Lo Bianco C , Schneider BL , Bauer M et al. (2004) Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha‐synuclein rat model of Parkinson's disease. Proceedings of the National Academy of Sciences of the USA 101(50): 17510–17515.

Luo J , Kaplitt MG , Fitzsimons HL et al. (2002) Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298(5592): 425–429.

Manfredsson FP , Burger C , Sullivan LF et al. (2007) rAAV‐mediated nigral human parkin over‐expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Experimental Neurology 207(2): 289–301.

Marks WJ Jr , Bartus RT , Siffert J et al. (2010) Gene delivery of AAV2‐neurturin for Parkinson's disease: a double‐blind, randomised, controlled trial. Lancet Neurology 9(12): 1164–1172.

Marks WJ Jr , Ostrem JL , Verhagen L et al. (2008) Safety and tolerability of intraputaminal delivery of CERE‐120 (adeno‐associated virus serotype 2‐neurturin) to patients with idiopathic Parkinson's disease: an open‐label, phase I trial. Lancet Neurology 7(5): 400–408.

Mittermeyer G , Christine CW , Rosenbluth KH et al. (2012) Long‐term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease. Human Gene Therapy 23(4): 377–381.

Moffat M , Harmon S , Haycock J and O'Malley KL (1997) l‐Dopa and dopamine‐producing gene cassettes for gene therapy approaches to Parkinson's disease. Experimental Neurology 144: 69–73.

Muramatsu S (2010) The current status of gene therapy for Parkinson's disease. Annals of Neurosciences 17(2): 92–95.

Muramatsu S , Fujimoto K , Ikeguchi K et al. (2002) Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno‐associated viral vectors expressing dopamine‐synthesizing enzymes. Human Gene Therapy 13(3): 345–354.

Muramatsu S , Fujimoto K , Kato S et al. (2010) A phase I study of aromatic l‐amino acid decarboxylase gene therapy for Parkinson's disease. Molecular Therapy 18(9): 1731–1735.

Oxford Biomedica (2011) Interim Data Analysis from On‐going Phase I/II Study of Safety, Efficacy and Dose Evaluation of ProSavin® for Mid‐ to Late‐stage Parkinson's Disease. Oxford, UK: Oxford Biomedica. Available at: http://www.oxfordbiomedica.co.uk/uploads/corporate‐presentation/2011‐oxb‐cp‐prosavin‐interim‐data‐analysis.pdf (accessed on 25 June 2013).

Shen Y , Muramatsu SI , Ikeguchi K et al. (2000) Triple transduction with adeno‐associated virus vectors expressing tyrosine hydroxylase, aromatic‐l‐amino‐acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Human Gene Therapy 11(11): 1509–1519.

Shingo T , Date I , Yoshida H and Ohmoto T (2002) Neuroprotective and restorative effects of intrastriatal grafting of encapsulated GDNF‐producing cells in a rat model of Parkinson's disease. Journal of Neuroscience Research 69(6): 946–954.

Vercammen L , Van der Perren A , Vaudano E et al. (2006) Parkin protects against neurotoxicity in the 6‐hydroxydopamine rat model for Parkinson's disease. Molecular Therapy 14(5): 716–723.

Wang L , Muramatsu S , Lu Y et al. (2002) Delayed delivery of AAV‐GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. Gene Therapy 9(6): 381–389.

Wang W , Sun M , Li H , Wang W and Yan M (2012) The delivery of tyrosine hydroxylase accelerates the neurorestoration of Macaca Rhesus model of Parkinson's disease provided by Neurturin. Neuroscience Letters 524(1): 10–15.

Yamada M , Mizuno Y and Mochizuki H (2005) Parkin gene therapy for alpha‐synucleinopathy: a rat model of Parkinson's disease. Human Gene Therapy 16(2): 262–270.

Yasuda T , Miyachi S , Kitagawa R et al. (2007) Neuronal specificity of alpha‐synuclein toxicity and effect of Parkin co‐expression in primates. Neuroscience 144(2): 743–753.

Further Reading

Coune PG , Schneider BL and Aebischer P (2012) Parkinson's disease: gene therapies. Cold Spring Harbor Perspectives in Medicine 2(4): a009431.

Kordower JH and Bjorklund A (2013) Trophic factor gene therapy for Parkinson's disease. Movement Disorders 28(1): 96–109.

Nakata Y , Yasuda T and Mochizuki H (2012) Recent progress in gene therapy for Parkinson's disease. Current Molecular Medicine 12(10): 1311–1318.

Yasuda T and Mochizuki H (2010) Use of growth factors for the treatment of Parkinson's disease. Expert Review of Neurotherapeutics 10(6): 915–924.

Related Sub-Topics:

Gene Therapy | Neurobiology of Disease
Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

Article Title: Gene Therapy for Parkinson Disease
 
How to Cite close
Choong, Chi‐Jing, and Mochizuki, Hideki(Nov 2013) Gene Therapy for Parkinson Disease. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0025023]